Vanguard Fiduciary Trust
ALLO icon

Vanguard Fiduciary Trust’s Allogene Therapeutics ALLO Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Buy
1,838,344
+746,535
+68% +$1.64M ﹤0.01% 2345
2026
Q1 		$2.66M Buy
+1,091,809
New +$2.19M ﹤0.01% 2420

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Fiduciary Trust's ALLO Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Allogene Therapeutics (ALLO) stake by 68% in Q2 2026, buying an estimated $1.64M and bringing the position to 1,838,344 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2345.

Vanguard Fiduciary Trust first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Vanguard Fiduciary Trust held 1,838,344 shares of Allogene Therapeutics worth $3.82M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 746,535 Allogene Therapeutics shares in Q2 2026, an estimated $1.64M.
  • Allogene Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2345 holding.
  • Vanguard Fiduciary Trust first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.